Abstract
Antimicrobial-resistant gram-negative bacilli (GNB) are a serious health problem worldwide. They have been associated with expanded patient mortality, delayed length of hospitalization, and increased clinic-related expenses.1,2 During the past decade, the problem worsened due to the emergence and rapid spread of metallo-β-lactamases (MBLs) that mediate resistance to carbapenems (ie, ertapenem, imipenem, and meropenem) among GNB, particularly among Acinetobacter spp, Pseudomonas aeruginosa, and Klebsiella spp.